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Introduction 
Primapterinuria is the recently discovered variant of 
hyperphenylalaninemia characterized by the excretion 
of 7-substituted pterins in the patients urine (1). Pri-
mapterinuria differs from the classical PKU and other 
variants of tetrahydrobiopterin deficiency because 
these patients do not need treatment with a low-
phenylalanine diet or with neurotransmitter precur-
sors L-DOPA and 5-hydroxytryptophan. The first 
patients were described by Dhondt et al. (2) and 
Blaskovics & Giudici (3). A loading test with tetra-
hydrobiopterin was the first indication that primap-
terin (7-biopterin) may derive from 6-biopterin (4). 
Tetrahydrobiopterin, dihydrobiopterin and sepiap-
terin given orally resulted in a significant increase in 
6- and 7-substituted biopterin, and the ratio remained 
the same (1.0 to 1.5) after loading (5). From in vitro 
experiments it is known that primapterin can be 
formed during the phenylalanine-4-hydroxylase re-
action in a pterin-4a-carbinolamine dehydratase free 
system (6). To the present time all known enzymes 
involved in the biosynthesis or regeneration of tetrah-
ydrobiopterin have been found to be normal in these 
patients and a pterin-4a-carbinolamine dehydratase 
deficiency has been proposed (Fig. 1). 
Results and Discussion 
Nine patients with this new disorder in the regener-
ation of tetrahydrobiopterin are now known. The 
infants initially present with variably elevated plasma 
phenylalanine (Phe) levels and are recognized in new-
born screening programs. The Phe levels may rise to 
the 25 to 35 mg% range. If started on a low-Phe diet 
the Phe levels fall rapidly and Phe often needs to be 
quickly replaced. Phe levels gradually decrease over 
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Figure 1. Phenylalanine-4-hydroxylase regenerating system and 
possible defect in primapterinuria. 
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Figure 2. 6-Biopterin, 7-biopterin (primapterin) and tetrahy-
drobiopterin (THB) in two children with primapterinuria at 
different ages. % T H B of the sum of all biopterins. 
N. B. = newborn 
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time to normal regardless of dietary Phe intake. Seven 
of the affected children are now on normal diets and 
Phe levels arc in the normal range; the two others are 
moving in that direction. These infants and children 
would fall into the category of transient hyperphen-
ylalaninemia/phenylketonuria unless they are identi-
fied by their urinary pterin profile. The only physical 
clinical findings of note have been transiently variable 
muscle tone, either hyper or hypo. In all instances, to 
the present time, the condition appears to be benign. 
All measurable substrates related to normal function-
ing have been present. The known phenylalanine hy-
droxylating system enzymes measured appear to be 
normal; however, phenylalanine-4-hydroxylase and 
pterin-4a-carbinolamine dehydratase, per se, have not 
been measured. The persisting abnormalities appear 
to be subnormal levels of tetrahydrobiopterin and 
elevated levels of primapterin (Fig. 2). It would appear 
that primapterin or its tetrahydro form has some 
effect on phenylalanine-4-hydroxylase. 
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